The role of regorafenib in the treatment of metastatic colorectal cancer


如何引用文章

全文:

详细

Regorafenib is a multi-tyrosine kinase inhibitor, associated with the activity in metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumors. Regorafenib application in patients with mCRC after exhausting all available drug therapies have resulted in statistically significant increase in life expectancy in comparison with best supportive therapy. This article discusses the issues concerning the efficacy, tolerability and the role of the drug in the treatment of refractory mCRC.

作者简介

A Tryakin

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

Email: atryakin@mail.ru
д-р мед. наук, ст. науч. сотр. отд-ния клинической фармакологии и химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

参考

  1. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
  2. Cremolini C, Loupakis F, Antoniotti C et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first - line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open - label, phase 3 TRIBE study. Lancet Oncol 2015; 16 (13): 1306-15.
  3. Stintzing S, Jung A, Rossius L et al. Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3 - A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first - line treatment for wild - type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. J Clin Oncol 2014; 32 (Suppl. 3; abstr. 445).
  4. Price T.J, Peeters M, Kim T.W et al. Panitumumab versus cetuximab in patients with chemotherapy - refractory wild - type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open - label, non - inferiority phase 3 study. Lancet Oncol 2014; 15 (6): 569-79.
  5. Amado R.G, Wolf M, Peeters M et al. Wild - type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26 (10): 1626-34.
  6. Wilhelm S.M, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129 (1): 245-55.
  7. Cyran C.C, Kazmierczak P.M, Hirner H et al. Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast - enhanced computed tomography with immunohistochemical validation. PLoS One 2013; 8 (9): e76009.
  8. Abou-Elkacem L, Arns S, Brix G et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 2013; 12 (7): 1322-31.
  9. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo - controlled, phase 3 trial. Lancet 2013; 381 (9863): 303-12.
  10. Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double - blind, placebo - controlled, phase 3 trial. Lancet Oncol 2015; 16: 619-29.
  11. Tougeron D, Desseigne F, Etienne P.L et al. REBECCA: a large cohort study of regorafenib (REG) in the real - life setting in patients (pts) previously treated for metastatic colorectal cancer (mCRC). Ann Oncol 2014; 25 (4): iv167-209.
  12. Van Cutsem E, Ciardiello F, Seitz J-F et al. Results from the large, open - label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. Ann Oncol 2015; 26 (Suppl. 4): iv118.
  13. Tabernero J, Lenz H.J, Siena S et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015; 16 (8): 937-48.
  14. Rechsteiner M, Wild P, Kiessling M.K et al. A novel germline mutation of PDGFR-beta might be associated with clinical response of colorectal cancer to regorafenib. Ann Oncol 2015; 26 (1): 246-8.
  15. Федянин М.Ю., Трякин А.А., Тюляндин С.А. Химиотерапия больных метастатическим раком толстой кишки. Онкологическая колопроктология. 2012; 2: 26-35.
  16. Karapetis C.S, Khambata-Ford S, Jonker D.J et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359 (17): 1757-65.
  17. Amado R.G, Wolf M, Peeters M et al. Wild - type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26 (10): 1626-34.
  18. Shitara K, Yamazaki K, Uetake H et al. Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild - type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE). J Clin Oncol 2014; 32 (Suppl.; abstr. TPS3662): 5s.
  19. Kidd M.T, Wilcox R.E, Rogers J et al. Efficacy of chemotherapy after treatment with regorafenib in metastatic colorectal cancer (mCRC). J Clin Oncol 2015; 33 (Suppl. 3; abstr. 678).
  20. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colon Cancer. Version 2.2016. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
  21. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. An Oncol 2014; 25 (Suppl. 3): iii1-ii9.
  22. Трякин А.А., Артамонова Е.В., Бесова Н.С. и др. Практические рекомендации по лекарственному лечению рака ободочной кишки. Злокачественные опухоли. 2015; 4 (Спецвып.): 214-29.

版权所有 © Consilium Medicum, 2016

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##